F. K. Habib
About
In The Last Decade
F. K. Habib
24 papers receiving 630 citations
Peers
Comparison fields: 5 of 61
- Pulmonary and Respiratory Medicine 355
- Endocrinology, Diabetes and Metabolism 231
- Molecular Biology 213
- Oncology 97
- Genetics 96
Countries citing papers authored by F. K. Habib
This map shows the geographic impact of F. K. Habib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. K. Habib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. K. Habib more than expected).
Fields of papers citing papers by F. K. Habib
This network shows the impact of papers produced by F. K. Habib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. K. Habib. The network helps show where F. K. Habib may publish in the future.
Co-authorship network of co-authors of F. K. Habib
This figure shows the co-authorship network connecting the top 25 collaborators of F. K. Habib. A scholar is included among the top collaborators of F. K. Habib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. K. Habib. F. K. Habib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | Alterations in the expression of androgen receptor, wild type-epidermal growth factor receptor and a mutant epidermal growth factor receptor in human prostate cancer. | 6 |
| 3 | Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. | 79 |
| 4 | Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA. | 6 |
| 5 | 8 | |
| 6 | Medical management of benign prostatic hyperplasia other than with hormones or alpha blockers. | 2 |
| 7 | 33 | |
| 8 | 72 | |
| 9 | 31 | |
| 10 | Hormones, growth factors and benign prostatic hyperplasia (BPH) | 3 |
| 11 | 19 | |
| 12 | 28 | |
| 13 | 56 | |
| 14 | 8 | |
| 15 | 2 | |
| 16 | 7 | |
| 17 | 17 | |
| 18 | 19 | |
| 19 | 55 | |
| 20 | 94 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.